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tiveness ratio (ICER) was calculated as cost ($CDN) per QALY
gained. QALYs were derived from the health assessment ques-
tionnaire (HAQ) scores collected prospectively on patients.
RESULTS: With the effectiveness-based analysis, the QALYs
gained during the 12-month monitoring period were estimated
to be 0.45 and 0.35, for the treatment and control groups respec-
tively. The resulting ICER was $167,282 (CDN) per QALY.
Using boot-strapping techniques and cost-effectiveness accept-
ability curves the 95% conﬁdence interval (CI) for the ICER was
$119,500 to $285,000 per QALY. For the efﬁcacy-based analy-
sis, the incremental QALYs gained were 0.56 and 0.35, for the
treatment and control groups respectively. This resulted in a sub-
stantially lower ICER, $81,213 per QALY [95% CI = 66,500,
103,430]. CONCLUSION: Depending on the data used for the
analysis, the resulting ICER was very different ($167,282 versus
$81,213 per QALY). This study highlights some the potential
concerns with using RCT data for estimating cost-effectiveness.
These results are consistent with, and help to explain, the dif-
ference in cost-effectiveness reported in 2 previous modeling
studies, one based on efﬁcacy data and the other based on effec-
tiveness data.
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Several cost-effectiveness studies have shown that the innovative
highly effective, but costly new biological therapies are within
acceptable ranges in rheumatoid arthritis (RA). The transfer-
ability of international results is limited. Country-speciﬁc data,
standardised methodologies are needed to study the adaptability
of cost-effectiveness models and to obtain comparable economic
evaluations. OBJECTIVES: The aim of our study was to assess
the burden and costs of the Hungarian RA population for the
purpose of further cost-effectiveness studies and modeling of bio-
logical therapies. METHODS: A cross sectional questionnaire
survey was performed in 2004 in 6 rheumatology centres focus-
ing on clinical characteristics, resource utilisation, EQ-5D and
HAQ were also used. A systematic search was performed in the
National Health Insurance Found database. RESULTS: A total
of 255 consecutive RA out-patients involved, mean age 55.3
years, females 86%, disease duration 9.12 years, HAQ 1.38,
DAS28 5.09, EQ-5D 0.46, DMARD therapy 87.9%, steroids
48%. Progression in HAQ correlates with utility (EQ-5D:
0.78–0.19). Costs: 55 % indirect costs (early retirement: 49%),
direct medical costs 28% (hospital admissions 11%); direct non-
medical costs 17% (informal care givers 15%). In 2000, 117,338
out-patient visits occurred with RA diagnosis. A total of 5089
patients were hospitalized because of RA (63528 bed-days, mean
duration 12.4 days), leading to about €1,340,000 consumption
of reimbursement. CONCLUSIONS: Our study investigated
Hungarian RA patients’ characteristics, health-care consumption
and burden of illness. The questionnaire survey included patients
with characteristics of target patients for biological therapy.
Health status utility decrease and costs increase consistently with
functional disability progression, early retirement and informal
care have major impact. Biological therapies are not reimbursed
yet in Hungary though arthritis centres network and guidelines
has been established. Our study offers standardized data for eco-
nomic analysis focusing on the adaptability of international cost-
effectiveness studies and models of biological therapies in the
Hungarian context.
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OBJECTIVES: Poor compliance/adherence has been shown to be
one of the leading causes for sub-optimal clinical beneﬁt. Overall
adherence in chronic diseases averages 50%, in rheumatoid
arthritis (RA) 50–70%. A comprehensive literature survey was
performed to explore the ﬁeld of compliance with biologic
DMARDs (bDMARDs), in particular regarding patient satisfac-
tion with different regimens, and to assess predicting factors of
compliance in RA treatment in general. METHODS: Relevant
articles were identiﬁed through search in a DIMDI Superbase (10
databases). Three search concepts were combined: compliance in
RA treatment 1) with bDMARDS, 2) with focus on different
administration modes 3) in general (reviews >1990). Addition-
ally, bibliographies and the Internet were reviewed. Juvenile
arthritis was excluded. RESULTS: Focus and approach of the
identiﬁed publications are highly varied. However, there are only
a few reliable data. So far, published compliance data with
bDMARDs are quasi limited to the ﬁrst two approved drugs.
Compliance rates of bDMARDs tend to be higher than those for
RA in general, calculated on basis of prescription reﬁlls (Olszyn-
ski 2004, Harley 2003). Patients’ preferences were evaluated in
three surveys. Two compared twice-weekly subcutaneous (SC)
injections with bi-monthly intravenous (IV) infusions, showing
a tendency in preference towards bi-monthly IV infusion. Factors
inﬂuencing compliance in RA treatment are older age, female
sex, decreased disability, and satisfactory contacts with health
care professionals (Viller 1999). Patient education showed posi-
tive (Viller 1999, Hill 2001) or no effects (Brus 1998). Less 
frequent dosing regimens (Claxton 2001) resulted in better com-
pliance, also bi-monthly IV infusion versus twice-weekly SC
injection (Jarry 2002). CONCLUSIONS: Compliance with
bDMARDs appears to be higher than with traditional RA treat-
ment. Patients’ preference regarding administration mode tends
towards IV infusion but needs further investigation, distinguish-
ing between kind and frequency of administration. Due to the
poor data compliance with bDMARDS needs further qualitative
and quantitative investigation.
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OBJECTIVES: To assess the ability of adalimumab + MTX to
improve health-related quality of life (HRQOL) in early RA and
interpret the results. METHODS: PREMIER was a 2-year study
of MTX-naïve, adult patients with early RA (<3 years) who
